Safety Study of Alfalastin (Human Alpha-1 Antitrypsin) Administered at Home

Laboratoire français de Fractionnement et de Biotechnologies17 enrolled

Overview

The purpose of this study is to collect safety data on ALFALASTIN® infusions performed at home or in out-of hospital locations.

Non interventional, observational, longitudinal, prospective, multicenter, non comparative study.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Alpha 1-Antitrypsin Deficiency

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Participation Criteria: * Patients above 18 y.o, * suffering from severe forms of primary alpha-1 antitrypsin deficiency, phenotype PiZZ or PiSZ with pulmonary emphysema, * currently treated as per routine practice, once a week, by ALFALASTIN® at home or in out-of-hospital location * and having signed informed consent.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.